nCounter® Myeloid Innate Immunity Panel

Helping Your Research

The nCounter® Myeloid Innate Immunity Panel provides comprehensive coverage of myeloid-derived cells in a targeted gene expression assay. These panels can be used with multiple sample types like peripheral blood mononuclear cells (PBMCs) or formalin-fixed paraffin-embedded (FFPE) tissue sections and provide results in less than 24 hours with minimal hands-on time and data analysis.  

The Myeloid Innate Immunity Panel is designed to encompass all aspects of the innate immune response of myeloid-derived cells and can be used for basic and translational research in immuno-oncology, autoimmunity, and infectious disease. The panel is curated to include the most current and relevant genes and is available in both human and mouse versions. Use the Myeloid Innate Immunity Panel to study: 

  • Mechanisms of immune evasion
  • Damage response, wound healing & tissue repair 
  • Immune regulation 
  • Disease pathogenesis 
  • Treatment response vs. non-response
Myeloid Innate Immunity

How It Works

The nCounter Myeloid Innate Immunity Panels were developed in collaboration with leading experts in the field of immuno-oncology but can be used to study the role of myeloid-derived cells whenever the innate immune system is implicated in the response to a disease or pathogen. Each panel enables characterization of the innate immune response by profiling genes involved in the recruitment and activation of selected myeloid subtypes.


770 genes In 19 different pathways and processes across 7 different myeloid cell types


Rapidly analyze Complex immune responses with publication-quality results next day


Optimized for difficult sample types including FFPE, PBMCs, or FACS sorted cells


Genes represent all major myeloid cell types including neutrophils, eosinophils, mast cells, dendritic cells, monocytes, and macrophages with 19 functional and pathway annotations


Customize with Panel Plus to spike-in up to 55 genes of your choice to tailor the panel for your research project

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Catalog Information
Catalog Information

Related Resources

See All Resources
Product Bulletin Myeloid Innate Immunity Panel – Product Bulletin
Poster AACR 2017 Poster_ Validation of human and mouse myeloid panels on the NanoString® nCounter® Platform


View All Publications

Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study.

Background: Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA) affect about 15% of critically ill patients with influenza or COVID-19, respectively. These viral–fungal coinfections are difficult to diagnose and are associated with increased mortality, but data on their pathophysiology are scarce.

Revisiting transplant immunology through the lens of single-cell technologies.

Solid organ transplantation (SOT) is the standard of care for end-stage organ disease. The most frequent complication of SOT involves allograft rejection, which may occur via T cell- and/or antibody-mediated mechanisms.

Activation of the Innate Immune Checkpoint CLEC5A on Myeloid Cells in the Absence of Danger Signals Modulates Macrophages’ Function but Does Not Trigger the Adaptive T Cell Immune Response.

C-Type lectin receptor 5A (CLEC5A) is a spleen tyrosine kinase- (Syk-) coupled pattern recognition receptor expressed on myeloid cells and involved in the innate immune response to viral and bacterial infections. Activation of the CLEC5A receptor with pathogen-derived antigens leads to a secretion of proinflammatory mediators such as TNF-α and IL-6 that may provoke a systemic cytokine storm, and CLEC5A gene polymorphisms are associated with the severity of DV infection.

Request a Quote

Contact our helpful experts and we’ll be in touch soon.